TY - JOUR
T1 - Clinical characteristics of subglottic cancer
T2 - emphasis on therapeutic management strategies for stage II subglottic cancer*
AU - Komatsubara, Yasutoshi
AU - Tachibana, Tomoyasu
AU - Orita, Yorihisa
AU - Makino, Takuma
AU - Kuroda, Kazunori
AU - Naoi, Yuto
AU - Kataoka, Yuko
AU - Sato, Yasuharu
AU - Kariya, Shin
AU - Nishizaki, Kazunori
N1 - Publisher Copyright:
© 2020 Acta Oto-Laryngologica AB (Ltd).
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Subglottic cancer (SGC) is extremely rare, as most laryngeal cancers are localized to the glottic region. Accordingly, the clinical characteristics of SGC have not been well characterized. Objectives: In the current study, SGCs were clinically evaluated, and the outcomes of radiotherapy (RT) in patients with stage II SGC were assessed. Materials and Methods: Medical data derived from 11 patients with SGC, who were treated at our hospital between 1995 and 2019, were retrospectively reviewed. Results: In our department SGC accounted for 3.9% of the 280 laryngeal cancer patients treated during the study period. At the time of SGC diagnosis, 9 (81.8%) had stage II cancer, 1 had stage III cancer, and 1 had stage IV cancer. Stage II SGC patients treated with concurrent chemoradiotherapy (CCRT) showed a significantly higher local control rate (p =.026) and laryngeal dysfunction free rate (p =.026) than those treated with RT alone. Salvage surgery, performed in 4 patients whose disease was not locally controlled with CCRT/RT, was successful in 3 patients. Conclusion: As a treatment strategy for stage II SGC, CCRT is an acceptable initial treatment for laryngeal function and preservation while salvage surgery is effective for recurrence after CCRT/RT treatment.
AB - Background: Subglottic cancer (SGC) is extremely rare, as most laryngeal cancers are localized to the glottic region. Accordingly, the clinical characteristics of SGC have not been well characterized. Objectives: In the current study, SGCs were clinically evaluated, and the outcomes of radiotherapy (RT) in patients with stage II SGC were assessed. Materials and Methods: Medical data derived from 11 patients with SGC, who were treated at our hospital between 1995 and 2019, were retrospectively reviewed. Results: In our department SGC accounted for 3.9% of the 280 laryngeal cancer patients treated during the study period. At the time of SGC diagnosis, 9 (81.8%) had stage II cancer, 1 had stage III cancer, and 1 had stage IV cancer. Stage II SGC patients treated with concurrent chemoradiotherapy (CCRT) showed a significantly higher local control rate (p =.026) and laryngeal dysfunction free rate (p =.026) than those treated with RT alone. Salvage surgery, performed in 4 patients whose disease was not locally controlled with CCRT/RT, was successful in 3 patients. Conclusion: As a treatment strategy for stage II SGC, CCRT is an acceptable initial treatment for laryngeal function and preservation while salvage surgery is effective for recurrence after CCRT/RT treatment.
KW - Radiotherapy
KW - stage II
KW - subglottic cancer
UR - http://www.scopus.com/inward/record.url?scp=85087055311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087055311&partnerID=8YFLogxK
U2 - 10.1080/00016489.2020.1767303
DO - 10.1080/00016489.2020.1767303
M3 - Article
C2 - 32491952
AN - SCOPUS:85087055311
VL - 140
SP - 773
EP - 778
JO - Acta Oto-Laryngologica
JF - Acta Oto-Laryngologica
SN - 0001-6489
IS - 9
ER -